Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Chipscreen's NDA for Novel Type 2 Diabetes Drug Accepted for China Review

publication date: Sep 20, 2019

Shenzhen Chipscreen Biosciences reported its new drug application for a first-in-class type 2 diabetes treatment was accepted for review in China. Chiglitazar, a novel small molecule peroxisome proliferator-activated receptor (PPAR) α/γ/δ pan-agonist, acts as an insulin sensitizer. The first PPAR pan-agonist to complete Phase III clinical trials, chiglitazar showed durable efficacy in glycemic control for patients with T2DM and metabolic syndrome. In August, Chipscreen completed a $147 million IPO on the Shanghai STAR board and rose 367% in its first trading day. More details....

Stock Symbol: (SHA: 688321)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.